Fifth CAR-T Cohort Dosed; Four Ovarian Cancer Patients Survive Beyond One Year
ANIX sits 29% above its 52-week low of $2.32.
Summary
Anixa finished dosing the fifth and highest cohort of its Phase 1 FSHR-targeted CAR-T trial in recurrent ovarian cancer at 1×10^7 CAR-positive cells/kg, with no dose-limiting toxicities across any cohort so far. The first patient in that cohort held stable disease 90 days out, and four patients have now passed one year of survival at roughly 28, 21, 17 and 17 months, one of them beyond two years. That follows the October 5 report of the first three-month stable-disease case and adds survival duration and a clean safety record at the top dose tested. For a company this small, the read-through is that the therapy is clearing its main hurdle — safety at escalating dose — which is what keeps a Phase 1 program alive. The sixth cohort at 1×10^8 cells/kg starts after a routine 30-day safety check on the fifth. Cash runway was stated at more than 12 months in the September 10-Q, so financing risk remains in the background while the trial advances.
At the time of this announcement, ANIX was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.9M. The 52-week trading range was $2.32 to $5.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.